MR Imaging of the Breast Using Gadolinium-DTPA

Heywang, Sylvia H.; Hahn, Dietbert; Schmidt, H; Krischke, Ingeborg; Eiermann, W.; Bassermann, R; Lissner, J

doi:10.1097/00004728-198603000-00005

Cited by 251 publications

(102 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since its introduction into clinical practice by Heywang-Kobruner in 1986 [10], DCE-MRI has almost unequivocally demonstrated high sensitivity for detection of breast cancer [11]. The main limitation of DCE-MRI in the investigation of breast lesions lies in its low specificity and the majority of studies in this field centred on the design of methods for improving the distinction between malignant and benign breast lesions.…”

Section: Introductionmentioning

confidence: 99%

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Radjenovic

Dall²,

Ridgway³

et al. 2008

BJR

View full text Add to dashboard Cite

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published versionRADJENOVIC, A., DALL, B. J., RIDGWAY, J. P. and SMITH, M. A. (2008). Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. British Journal of Radiology, 81 (962), 120-128. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 This paper presents a practical clinical application of a quantitative pharmacokinetic model to study histologically confirmed and graded invasive human breast tumours. The hypothesis was that, given a documented difference in capillary permeability between benign and malignant breast tumours, a relationship between permeability-related DCE-MRI parameters and tumour aggressiveness persists within invasive breast carcinomas. In addition, it was hypothesised that pharmacokinetic parameters may demonstrate stronger correlation with prognostic factors than the more conventional black-box techniques, so a comparison was undertaken. Copyright and re-use policySignificant correlations were found between pharmacokinetic and black-box parameters in 59 invasive breast carcinomas. However, statistically significant variation with tumour grade was only demonstrated in two permeability related pharmacokinetic parameters: k ep (p<0.05) and K trans

show abstract

Section: Introductionmentioning

confidence: 99%

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Radjenovic

Dall²,

Ridgway³

et al. 2008

BJR

View full text Add to dashboard Cite

show abstract

“…27 Since then several other GBCAs have been evaluated. Renz et al evaluated 45 patients with gadoteric acid and gadobutrol and while some differences were noted in terms of the dynamic and morphologic characterization of breast lesions, both GBCAs were considered reliable for breast MRI.…”

Section: Gbcas and Breast Mrimentioning

confidence: 99%

Clinical utility of gadobenate dimeglumine in contrast-enhanced MRI of the breast: a review

Luciani¹,

Telesca²,

Kirchin³

et al. 2015

RRNM

View full text Add to dashboard Cite

Breast magnetic resonance imaging (MRI) is considered the technique with the highest sensitivity for breast cancer detection. Gadobenate dimeglumine is a gadolinium-based contrast agent (GBCA) that is specifically approved in Europe for breast MRI and which has the highest r1 relaxivity among all GBCAs for this indication. In order to improve the diagnostic performance of breast MRI, several intra-individual crossover studies have evaluated gadobenate dimeglumine as a possible GBCA for this application. This review focuses on the role and advantages of gadobenate dimeglumine as a contrast agent for breast MRI by describing the unique properties of this agent and by summarizing published studies.

show abstract

“…CE MRI employs magnetic and radio frequency fields to visualize the uptake of an MRI-specific contrast agent (gadolinium-DTPA) [30]. Applied intravenously, this agent results in enhancement of areas in the breast that correspond to increased blood flow, capillary permeability, and extracellular volume [31,32].…”

Section: Ce Mri Of Symptomatic Womenmentioning

confidence: 99%

MRI in familial breast cancer

Gilhuijs

Deurloo

2004

Breast Cancer Online

View full text Add to dashboard Cite

Five to ten per cent of all breast cancers are associated with a proven genetic predisposition for the disease or a strong family history of breast cancer in which yet unknown genetic predisposition is suspected. Carriers of germline mutations in genes breast cancer 1 or 2 (BRCA1/2) have up to 85% chance of developing breast cancer during their lifetime. The majority of these women develop the disease before the age of 50 years. Consequently, breast-cancer screening programmes aimed at reducing mortality in this population may only be effective if they start at much younger age than the general breast-cancer screening programmes. Unfortunately, the efficacy of conventional X-ray mammography in premenopausal women is often limited by dense fibroglandular tissue that obscures suspicious lesions. As a result, more advanced breast-imaging techniques have been considered, such as contrast-enhanced (CE) magnetic resonance imaging (MRI). In symptomatic patients, the sensitivity of CE MRI to detect invasive breast cancer is known to be high, regardless of the density of the fibroglandular tissue. Conversely, the specificity of CE MRI to discriminate between benign and malignant lesions is variable, and depends on the indication of the examination. Low specificity could result in many recalls on benign lesions, thus negatively affecting the cost–benefit ratio of CE MRI as a screening technique. Several single- and multi-institutional studies have been performed to investigate the efficacy of CE MRI as a screening tool exclusively for asymptomatic women at increased lifetime risk of breast cancer. Mounting evidence suggests that the addition of CE MRI results in cost-effective detection of tumours at earlier stage in BRCA1/2 mutation carriers. The value of CE MRI in other populations at risk is currently uncertain, and it is unlikely that CE MRI will be cost efficient in the general screening population of women who are not at increased lifetime risk.

show abstract

MR Imaging of the Breast Using Gadolinium-DTPA

Cited by 251 publications

References 0 publications

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI

Clinical utility of gadobenate dimeglumine in contrast-enhanced MRI of the breast: a review

MRI in familial breast cancer

Contact Info

Product

Resources

About